A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications B cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms PILOT
- Sponsors Celgene Corporation
- 20 Jun 2018 Status changed from not yet recruiting to recruiting.
- 14 May 2018 Planned End Date changed from 15 Jun 2022 to 2 Aug 2022.
- 14 May 2018 Planned primary completion date changed from 15 Jun 2022 to 2 Aug 2022.